Tasimelteon

Active ingredient: Tasimelteon

In short: Tasimelteon capsules are indicated for the treatment of Non-24 in adults.

Forms & strengthsCapsules: 20 mg hard gelatin capsule with dark blue, opaque body and dark blue, opaque cap. Imprinted “APO” and “TAS” over “20” in white ink.
LabelApotex Corp.
Label updatedSep 21, 2026

What is Tasimelteon used for?

Tasimelteon capsules are indicated for the treatment of Non-24 in adults.

Tasimelteon dosage

Tasimelteon capsules and tasimelteon oral suspension are not substitutable .

Adults

The recommended dosage of tasimelteon capsules in adults is 20 mg one hour before bedtime, at the same time every night.

Because of individual differences in circadian rhythms, drug effect may not occur for weeks or months.

Administer tasimelteon capsules without food .

If a patient is unable to take tasimelteon capsules at approximately the same time on a given night, they should skip that dose and take the next dose as scheduled.

How to take Tasimelteon — instructions & advice from the label

Advise patients to limit their activities to preparing for going to bed after taking tasimelteon capsules because tasimelteon can potentially impair the performance of activities requiring complete mental alertness .

Administration Information for tasimelteon capsules .

Advise patients to take tasimelteon capsules without food.

Advise patients to take tasimelteon capsules before bedtime at the same time every night.

Advise patients to skip the dose that night if they cannot take tasimelteon capsules at approximately the same time on a given night.

Advise patients to swallow tasimelteon capsules whole.

Non-24 (tasimelteon capsules)Advise patients that because of individual differences in circadian rhythms, daily use for several weeks or months may be necessary before benefit from tasimelteon capsules is observed .

APOTEX INC.

TASIMELTEON CAPSULES

20 mg

Manufactured By

Apotex Inc. Toronto, Ontario Canada M9L 1T9 | Manufactured For

Apotex Corp. Weston, Florida USA 33326

Rev. 5

Warnings & precautions

Do not take this medicine if: None.

After taking tasimelteon capsules, patients should limit their activity to preparing for going to bed. Tasimelteon capsules can potentially impair the performance of activities requiring complete mental alertness.

Tasimelteon side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

More than 2080 subjects have been treated with at least one dose of tasimelteon, of which more than 380 have been treated for > 26 weeks and more than 170 have been treated for > 1 year.

Non-24-Hour Sleep-Wake Disorder (Non-24)

A 26-week, parallel-arm placebo-controlled study (Study 1) evaluated tasimelteon (n=42) compared to placebo (n=42) in patients with Non-24. A randomized-withdrawal, placebo-controlled study of 8 weeks duration (Study 2) also evaluated tasimelteon (n=10), compared to placebo (n=10), in patients with Non-24.

In placebo-controlled studies, 6% of patients exposed to tasimelteon discontinued treatment due to an adverse event, compared with 4% of patients who received placebo.

Table 2 shows the incidence of adverse reactions from Study 1.

Table 2: Adverse Reactions in Study 1

Tasimelteon

N=42 | Placebo

N=42

Headache | 17 % | 7 %

Alanine aminotransferase increased | 10 % | 5 %

Nightmare/abnormal dreams | 10 % | 0 %

Upper respiratory tract infection | 7 % | 0 %

Urinary tract infection | 7 % | 2 %

*Adverse reactions with an incidence > 5% and at least twice as high on tasimelteon than on placebo are displayed.

Drug interactions

Avoid use of tasimelteon in combination with fluvoxamine or other strong CYP1A2 inhibitors because of a potentially large increase in tasimelteon exposure and greater risk of adverse reactions .

Avoid use of tasimelteon in combination with rifampin or other CYP3A4 inducers because of a potentially large decrease in tasimelteon exposure with reduced efficacy .

Beta-adrenergic receptor antagonists have been shown to reduce the production of melatonin via specific inhibition of beta-1 adrenergic receptors. Nighttime administration of beta-­adrenergic receptor antagonists may reduce the efficacy of tasimelteon.

About this medicine

Tasimelteon is a melatonin receptor agonist, chemically designated as (1R-trans)-N-[[2-(2,3-Dihydrobenzofuran-4-yl)cycloprop-1-yl]methyl]propanamide, containing two chiral centers. The molecular formula is C15H19NO2, and the molecular weight is 245.32 g/mol. The structural formula is:

Tasimelteon is a white to off-white powder. It is very slightly soluble in cyclohexane, slightly soluble in water and freely soluble or very soluble in methanol, 95% ethanol, acetonitrile, isopropanol, propylene glycol and ethyl acetate.

Tasimelteon capsules are intended for oral administration. Each capsule contains 20 mg of tasimelteon and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. Each hard gelatin capsule consists of FD&C Blue #1, FD&C Red #3, and FD&C Yellow #6, gelatin and titanium dioxide. The imprinting ink consists of povidone, propylene glycol, shellac, sodium hydroxide and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 46b09064-a675-92d5-24a7-dac0410f77ae. Read the full official label on DailyMed.